Xantinol nicotinate - instructions for use, dose, side effects, contraindications

Combination of the effects of theophylline and nicotinic acid, enhancement of oxidative phosphorylation and synthesis of ATP; blockade of adenosine receptors and phosphodiesterase, an increase in the content of cAMP in the cell, substrate stimulation of the synthesis nicotinadenine dinucleotide and nicotinamide adenine dinucleotide phosphate. Has vasodilator and anti-atherosclerotic effect.

Pharmacokinetics:

The drug is well absorbed in the digestive tract, in the body quickly turns first into theophylline and nicotinic acid, then into their metabolites. Excreted mainly by the kidneys in the form of metabolites. With intramuscular injection, the effect develops after 5-10 minutes.

Indications:

Disorders of cerebral circulation.

Atherosclerosis of cerebral vessels, coronary vessels and obliterating atherosclerosis of the vessels of the lower extremities.

Raynaud's disease.

Burgess's disease.

Retinopathy.

Obliterating endarteritis.

Acute arterial thrombosis.

Diabetic angiopathy.

Acute thrombophlebitis and postthrombophlebitic syndrome.

Trophic ulcers of lower limbs and pressure sores.

Migraine.

Meniere's syndrome.

Dermatoses.

Hypercholesterolemia, hypertriglyceridemia.

Intrauterine and postnatal fetal asphyxia.

ICD-10

VI.G40-G47.G43 Migraine

VII.H30-H36.H35 Other retinal diseases

VIII.H80-H83.H81.0 Ménière's disease

IX.I60-I69.I67.2 Cerebral atherosclerosis

IX.I70-I79.I70.2 Atherosclerosis of the arteries of the extremities

IX.I70-I79.I70 Atherosclerosis

IX.I70-I79.I73.0 Raynaud's syndrome

IX.I70-I79.I74 Embolism and thrombosis of the arteries

IX.I70-I79.I79.2 * Peripheral angiopathy in diseases classified elsewhere

IX.I80-I89.I80 Phlebitis and thrombophlebitis

XII.L80-L99.L87 Transepidermal perforated changes

XII.L80-L99.L98.9 Lesion of skin and subcutaneous tissue, unspecified

Contraindications:

Individual intolerance.

Severe congestive heart failure.

Acute bleeding.

Acute myocardial infarction.

Stomach ulcer and duodenal ulcer in the stage of exacerbation.

Carefully:

With labile arterial pressure, simultaneously with antihypertensive drugs, in drivers of vehicles, as well as in patients engaged in potentially hazardous activities.

Pregnancy and lactation:

The category of FDA recommendations is not defined. Adequate and well-controlled studies in humans and animals have not been conducted. Do not use in the first 3 months of pregnancy. Further use is permissible provided that the patient is carefully monitored.

There is no information on the penetration into breast milk. Do not apply!

Dosing and Administration:

Inside with a gradual increase in the dose from 150 mg 3 times a day to 300-600 mg 3 times a day if necessary. The drug is taken after a meal.

Intramuscularly introduce 2-6 ml of 15% solution for 2-3 weeks.

Intravenously jet - 2 ml of 15% solution 1-2 times a day for 5-10 days, while the patient must lie.

Intravenously drip injected at a rate of 40-50 drops per minute after dilution 10 ml of 15% solution in 200-500 ml of 5% glucose solution or in 200 ml isotonic sodium chloride solution.

Side effects:

The cardiovascular system: Arterial hypotension, transient sensation of heat, reddening of the skin.

Nervous system: weakness, dizziness.

Digestive system: nausea, diarrhea, anorexia, pain in the stomach.

With long-term administration of high doses - a decrease in glucose tolerance, an increase in liver transaminases and alkaline phosphatase, hyperuricemia.

Overdose:No data.

Interaction:

With simultaneous use, the effect of antihypertensive drugs (alpha and beta adrenoblockers, ergot alkaloids, sympatholytics, ganglioblocators) is mutually reinforced.

Caution should be exercised with simultaneous administration with antihypertensive agents and strophanthin.

Special instructions:No data.

Instructions

Xantinol nicotinate (Xantinoli nicotinas)